Clinical, Histopathological, and Molecular Features of IDH-wildtype Indolent Diffuse Glioma: Comparison with Typical Glioblastoma

Overview

Journal J Neurooncol

Publisher Springer

Date 2022 Jul 2

PMID 35779193

Authors

Hayato Suzuki

Takahiro Ono

Souichi Koyota

Masataka Takahashi

Tamotsu Sugai

Hiroshi Nanjo

Hiroaki Shimizu

Affiliations

Soon will be listed here.

Abstract

Purpose: IDH-wildtype (IDHwt) diffuse gliomas are treated as glioblastoma, however, some of these may show less aggressive clinical courses. The authors investigated the clinical, histopathological, and molecular characteristics of such IDHwt indolent diffuse gliomas (iDGwt), which have not been well documented in the literature.

Methods: Adult patients with IDHwt gliomas admitted between 2011 and 2020 were surveyed. In this particular study, the clinical indolence was defined mainly as having a small enhancing lesion and a stable period for more than 1 month before surgery. The current WHO diagnostic criteria were adapted for the diagnoses. Gene mutations and copy number changes in 43 representative glioma-associated genes, MGMT promoter methylation status, and survival data were compared with those of The Cancer Genome Atlas reference cohort.

Results: Nine out of 180 surveyed cases (5.0%) fulfilled the present criteria of the iDGwt. Considering the representative regulatory pathways, 8 (88.9%), 4 (44.4%), and 1 (11.1%) case had genetic alterations in the PI3K/MAPK, TP53, and RB pathways, respectively. The frequency of the RB pathway alteration was significantly lower than that in the reference cohort (281 of 362 cases: 77.6%). Two cases (22.2%) showing EGFR amplification met the diagnostic criteria for glioblastoma, and the frequency was significantly lower than that in the reference cohort (412 of 426 cases: 96.7%). The overall survival (median: 37.5 months) in the present series was significantly longer than that in the reference cohort (n = 426, median: 13.9 months).

Conclusions: iDGwt lacked the molecular features of glioblastoma except for the PI3K/MAPK pathway alteration.

Citing Articles

Genetic Discrimination of Grade 3 and Grade 4 Gliomas by Artificial Neural Network.

Mekler A, Schwartz D, Savelieva O Cell Mol Neurobiol. 2023; 44(1):13.

PMID: 38150033 PMC: 11407181. DOI: 10.1007/s10571-023-01448-z.

References

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B . Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23):2306-2316. PMC: 5820703. DOI: 10.1001/jama.2017.18718. View

Ellingson B, Nguyen H, Lai A, Nechifor R, Zaw O, Pope W . Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. Cancer. 2016; 122(11):1718-27. DOI: 10.1002/cncr.29957. View

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss D, Sahm F . Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018; 136(1):153-166. DOI: 10.1007/s00401-018-1849-4. View

STEINHOFF H, Lanksch W, KAZNER E, Grumme T, Meese W, Lange S . Computed tomography in the diagnosis and differential diagnosis of glioblastomas. A qualitative study of 295 cases. Neuroradiology. 1977; 14(4):193-200. DOI: 10.1007/BF00496983. View

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

Daumas-Duport C, Scheithauer B, OFallon J, Kelly P . Grading of astrocytomas. A simple and reproducible method. Cancer. 1988; 62(10):2152-65. DOI: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t. View

Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H . Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol. 2014; 32(1):22-30. DOI: 10.1007/s10014-014-0186-0. View

Sahm F, Schrimpf D, Jones D, Meyer J, Kratz A, Reuss D . Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2015; 131(6):903-10. DOI: 10.1007/s00401-015-1519-8. View

10.

Brennan C, Verhaak R, McKenna A, Campos B, Noushmehr H, Salama S . The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462-77. PMC: 3910500. DOI: 10.1016/j.cell.2013.09.034. View

11.

Brat D, Verhaak R, Aldape K, Yung W, Salama S, Cooper L . Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015; 372(26):2481-98. PMC: 4530011. DOI: 10.1056/NEJMoa1402121. View

12.

Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y . Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015; 47(5):458-68. DOI: 10.1038/ng.3273. View

13.

Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View

14.

Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M . Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018; 136(5):793-803. DOI: 10.1007/s00401-018-1905-0. View

15.

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A . Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 2019; 110(4):1480-1490. PMC: 6447843. DOI: 10.1111/cas.13969. View

16.

French P, Eoli M, Sepulveda J, de Heer I, Kros J, Walenkamp A . Defining EGFR amplification status for clinical trial inclusion. Neuro Oncol. 2019; 21(10):1263-1272. PMC: 6784284. DOI: 10.1093/neuonc/noz096. View

17.

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

18.

Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23(6):703-713. PMC: 5461196. DOI: 10.1038/nm.4333. View

19.

Yamamoto E, Suzuki H, Yamano H, Maruyama R, Nojima M, Kamimae S . Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Am J Pathol. 2012; 181(5):1847-61. DOI: 10.1016/j.ajpath.2012.08.007. View

20.

Yuan G, Niu L, Zhang Y, Wang X, Ma K, Yin H . Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. J Neurooncol. 2017; 133(1):193-201. DOI: 10.1007/s11060-017-2433-9. View